Skip to main content
OpenTrials
Completed

NCT Number: NCT01955057

Study of Psychopathological Characteristics of Patient Smoking in Thoracic Oncology

Persistent smoking after lung cancer has been the subject of medical, therapeutic and epidemiological publications for twenty years of research. Continued persistent smoking is all the more a problem for oncologists as there is evidence that smoking cessation, with lung cancer, gives therapeutic benefit. Quitting smoking can improve the response to treatments (chemotherapy, radiotherapy, surgery), quality of life and overall survival. However many patients refuse adhesion to tobacco cessation. Daily practice leads us to the hypothesis that adhesion differences aren't related to the denial of medical information, nor to resignation or to nicotine dependence. Patients who continue smoking seem to face a form of impossibility to wean. Cigarette seems to be felt as a part of their body in their narration and description of their body image.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Smoking Cessation and Lung Cancer Behavior Health Behavior Lung Diseases Lung Neoplasms Neoplasms Neoplasms by Site Respiratory Tract Diseases Respiratory Tract Neoplasms Smoking Cessation Thoracic Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Nouvel Hôpital Civil, Service de pneumologie, Unité de cancérologie thoracique, Hôpitaux Universitaires de Strasbourg

Strasbourg, 67091, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Men and women aged 18 years or older
  • Patient affiliated to a social security system
  • Patient who has signed and dated informed consent, written before all procedures related to the study
  • Patient who has received the results of the previous mandatory medical examination
  • Patient who has been diagnosed with lung cancer, regardless of the histological type of the cancer
  • Patient who maintains an active smoking at the time of inclusion
  • Patient who has smoked at least one cigarette in the previous year of inclusion
  • Patient who is being treated for lung cancer (surgery, chemotherapy, radiotherapy) and not another form of cancer
  • Tobacco consumer's only by smoke inhalation
  • Tobacco consumer's or tobacco associated with cannabis

Exclusion criteria

  • Major patient under guardianship or curatorship or maintenance of justice
  • Patient deprived of his liberty or in an emergency situation
  • Patient with a Performance Statut(OMS) higher than 2 and/or with a psychiatric disorder like " schizophrenia and other psychotic disorders " (DSM IV)
  • A palliative care patient
  • Patient who began smoking during his diagnostic examination or after the diagnosis of cancer
  • A pregnant or breastfeeding woman
  • Patient in an exclusion period

Treatment and study plan

Research interviews

Behavioral

Tests (Fagerström, Q-MAT, H.A.D.S, SCL 90-R)

Behavioral

Projective methods (Thematic apperception Test, Rorschach)

Behavioral

Carbon monoxide test

Behavioral

Primary outcomes

  1. Composite indicator variable indicating the presence or absence of disturbance in one or more of the parameters evaluated: object relations, body, subject's choice.

    Time frame: 2 months after inclusion

    The results will be obtained:

    • From the results of each test, each has indeed a standardized rating scale
    • By analysing the content of the speech of the patient previously noted during the various interviews The investigator will classify each subject in "disturbance" or not for each of the three parameters. The presence of at least one disturbance gives the "yes" value in the indicator variable, "no" in the absence of the three disturbances.

  2. Composite indicator variable indicating the presence or absence of disturbance in one or more of the parameters evaluated: object relations, body, subject's choice.

    Time frame: 4 months after inclusion

    The results will be obtained:

    • From the results of each test, each has indeed a standardized rating scale
    • By analysing the content of the speech of the patient previously noted during the various interviews The investigator will classify each subject in "disturbance" or not for each of the three parameters. The presence of at least one disturbance gives the "yes" value in the indicator variable, "no" in the absence of the three disturbances.

Sponsors and collaborators

Lead sponsor

University Hospital, Strasbourg, France

Other

Registry information

Important dates

Study start
2013
Primary completion
2016
Study completion
2016
First posted
Oct 7, 2013
Registry last updated
Jun 9, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.